Aetna announced, Thursday, Aug. 16, it will expand its coverage of the PET tracer gallium-68 (Ga-68) dotatate, according to a Society of Nuclear Medicine and Molecular Imaging (SNMMI) release. The radiopharmaceutical is now considered “medically necessary.”